ASH 2017 Recap: These Were the Big Winners and Losers

The American Society of Hematology's (ASH) conference is one of biopharma's biggest annual events. This year's meeting was packed with market-moving presentations, but perhaps the biggest showstopper was data from companies working on gene therapies.

For example, bluebird bio (NASDAQ: BLUE), Juno Therapeutics (NASDAQ: JUNO), Spark Therapeutics (NASDAQ: ONCE), and BioMarin (NASDAQ: BMRN) unveiled trial results for therapies that could someday become billion-dollar blockbusters. Investors didn't react to each company's results in the same way, though. Juno Therapeutics and Spark Therapeutics saw their share prices stagger, while bluebird bio's shares soared.

In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell discuss how gene therapies at these companies could reshape cancer and hemophilia treatments, and why investors reacted to the news the way they did.

Continue reading

Source: Fool.com